Genetically-engineered mouse models Professors and Supervisors | ApplySharif

Find Academic Supervisors

Find and connect with academic supervisors, professors, and scholars for your research journey.

Showing 721-735 of 2,839 supervisors

Profile data may be stale. It is sourced from public faculty pages.

Wei ZhangView profile

Assistant Professor

Temple UniversityUnited States

Wei Zhang, PhD is an Assistant Professor in the Department of Cardiovascular Sciences at the Lewis Katz School of Medicine, Temple University. His research focuses on vascular wall disorders, smooth muscle cell (VSMC) phenotypic changes, and therapeutic target discovery. BSc in Pharmacy - Sun Yat-Sen University PhD in Biomedical Engineering - Sun Yat-Sen University Dr. Zhang’s work explores how VSMC heterogeneity contributes to pathologies like restenosis, aneurysm dissection, and atherosclerosis. He investigates mechanisms of VSMC proliferation, migration, and transdifferentiation using genetic, surgical, and dietary rodent models, including conditional knockout mice and lineage-tracing systems. His publications highlight advancements in single-cell transcriptomics, lncRNA (INKILN) targeting, and prime editing for tissue-specific gene function. Articles span Redox Biology , Circulation , Genome Biology , and Aging (Albany NY) , with trends in multiomics, gene editing, and aging-related vascular pathways. Scientific Awards: 2023 AHA Transformational Project Award 2023 AHA Second Century Early Faculty Independence Award 2023 Augusta University Intramural Grant 2023 ATVB Travel Grant for Early Career Investigators 2018 AHA Career Development Award Dr. Zhang’s lab utilizes humanized transgenic mice, lineage-tracing models, and cell cycle/senescence reporters to study vascular disease initiation and progression at high resolution.

Official University Profile

James HughesView profile

Lecturer

The University of AdelaideAustralia

Dr James Hughes is a Lecturer at the Centre for STEM Education and Innovation , part of the Faculty of Sciences, Engineering and Technology at the University of Adelaide. His expertise lies in the fatigue and fracture of metals , with a focus on predicting crack growth and measuring crack opening loads . He remains an active researcher in these fields. As a co-supervisor, Dr Hughes supports postgraduate students at the Masters and PhD levels , emphasizing practical research in metallurgy and structural integrity. His contact details include james.m.hughes@adelaide.edu.au . While specific scientific awards are not mentioned in his current profile, his work contributes to structural engineering and materials science through both theoretical and experimental approaches.

Official University Profile

Gabriele Fischer von MollardView profile

Professor

Bielefeld UniversityGermany

Prof. Dr. Gabriele Fischer von Mollard is a leading researcher at Bielefeld University's Faculty of Chemistry , holding the Biochemistry III professorship since 2005. She previously held positions at Ruhr University Bochum (2004) and University of Göttingen (1998-2004) where she led a junior research group funded by the Volkswagen Foundation. University studies in Biochemistry at Tübingen, Munich, and Berlin Diploma (1989) and PhD (1992) from Free University of Berlin Habilitation (2002) at University of Göttingen Her research focuses on membrane transport mechanisms , particularly the molecular roles of SNARE proteins in yeast and mammalian cells. Current projects include: Investigating NDRG3-GOSR2 interactions in ER-Golgi transport Characterizing SNARE protein deficiencies (vti1a/b) in neuronal development Engineering fungal L-amino acid oxidases for biocatalytic applications Recent publications highlight both fundamental discoveries in vesicular transport (15+ articles 2021-2025) and applied biocatalysis projects involving enzyme immobilization technologies. Her work bridges basic science with industrial applications through collaborations in enzyme engineering and protein production systems.

Official University Profile

C. Julie ChangView profile

Researcher

University of California, Los AngelesUnited States

Dr. C. Julie Chang is a Full-Time Faculty Researcher at the University of California, Los Angeles specializing in molecular microbiology with over 15 years of expertise in bacterial pathogenesis and oral biofilm development. Her work focuses on the role of bacterial cell surface virulence factors in polymicrobial interactions during periodontitis, utilizing biochemical and genetic approaches to study Gram-positive pathogens. Education: B.S. in Biology, Tunghai University, Taichung, Taiwan, 1984 Ph.D. in Microbiology, Texas A&M University, College Station, Texas, 1994 Chang's research integrates protein biochemistry and engineering to innovate therapeutic treatments for oral diseases. She investigates sortase-mediated pilus assembly mechanisms in pathogens like Corynebacterium diphtheriae and Fusobacterium nucleatum , revealing how bacterial surface structures drive biofilm formation and host tissue destruction in periodontitis. Her work bridges fundamental molecular mechanisms with clinical applications for dental disease prevention. Analysis of her 35+ publications shows consistent focus on Gram-positive bacterial surface assembly, with recent work expanding into oxidative stress defense systems and polymicrobial virulence networks. Key trends include structural characterization of sortase enzymes, identification of novel virulence determinants, and development of therapeutic strategies targeting bacterial adhesion mechanisms. Scientific Awards: U.S. Patent No. 5,777,078: Triggered Pore Forming Agents Chang has supervised numerous graduate students and postdoctoral researchers while managing laboratory operations for the Ton-That research group. She has led collaborative projects resulting in high-impact publications in journals including Proceedings of the National Academy of Sciences , with research funded through institutional grants focused on oral bacterial pathogenesis. Her laboratory employs biochemical, genetic, and structural methodologies to dissect bacterial surface assembly pathways critical for polymicrobial biofilm development in the oral cavity.

Official University Profile

Mara E. PitulescuView profile

Research Professor

University of MünsterGermany

Dr. Mara E. Pitulescu serves as Research Group Leader at the Max Planck Institute for Molecular Biomedicine in Münster, Germany, heading the Vascular Patterning Dynamics laboratory. She is actively involved in the "Cells in Motion" research network, serves as Supervisor in the CiM-IMPRS Graduate Programme, and is a Member of the Imaging Network – Microscopy. Her research focuses on endothelial cell biology, angiogenesis, arterial formation, tissue patterning, and organogenesis. Dr. Pitulescu investigates how endothelial cells make fate decisions and dynamically communicate to control vascular network assembly during development and disease. Her laboratory employs advanced methodologies including mouse genetics, high-resolution imaging, in vitro models, biochemical assays, and next-generation sequencing techniques to decode molecular mechanisms of vascular patterning. Analysis of her publication record reveals a consistent focus on vascular development mechanisms, particularly artery formation. Her work bridges fundamental cell biology with potential applications in tissue engineering and regenerative medicine, addressing the critical challenge of vascularization in engineered tissues. Dr. Pitulescu actively mentors graduate students through the CiM-IMPRS program and collaborates within multiple research networks. Her laboratory receives funding from the Max Planck Society (MPG), the German Research Foundation (DFG), and CRC1348 (SFB/Collaborative Research Center 1348), with previous support from FOR2325. The Vascular Patterning Dynamics laboratory investigates how endothelial cells adapt their behavior according to vascular bed, functionality, and organ environment to coordinate vascular network assembly. Current research examines organ-specific vascular patterning mechanisms and arterial formation in both health and disease contexts, with implications for improving vascularization in engineered tissues.

Official University Profile

Sheri HolmenView profile

Professor

University of UtahUnited States

Sheri Holmen, Ph.D. is a Professor of Surgery and Adjunct Professor of Oncological Sciences at the University of Utah, and co-leads the Cell Response and Regulation Program and Melanoma Center at the Huntsman Cancer Institute (HCI). Her laboratory employs sophisticated genetically-engineered mouse models to dissect the molecular circuitry governing melanoma and glioblastoma initiation, progression, and therapeutic resistance. Education: B.S. – Western Michigan University Ph.D. – Mayo Clinic College of Medicine Research Focus: Dr Holmen’s team concentrates on high-priority oncogenic pathways—PI3K/AKT/mTOR, MAPK, and focal adhesion kinase (FAK)—leveraging conditional RCAS/TVA retroviral systems to introduce precise genetic alterations in melanocytes and neural progenitors. The overarching goal is to uncover tractable therapeutic targets for metastatic melanoma and glioblastoma, particularly brain metastases that portend dismal prognosis. Scientific Impact & Trends: Across more than 100 peer-reviewed publications since 2012, Holmen’s group has demonstrated convergent mechanisms of resistance to BRAF/MEK inhibition, identified ARF6-mediated immune evasion, and validated combinatorial FAK + RAF/MEK blockade as a strategy to overcome micro-environmental resistance. Their 2024–2025 output emphasises metabolic liabilities (OXPHOS, CNDP1) and rational immunotherapy combinations. Current Funding & Collaborations: Principal investigator on multiple NCI-funded R01 and P30 awards via HCI. Founding steering committee member of the international InterMEL consortium (>2,000 early-stage melanomas) to discover prognostic biomarkers. Co-investigator on Utah Genome Project and Oncology Research Information Exchange Network initiatives. Laboratory & Resources: The Holmen laboratory occupies modern space within the HCI research tower and maintains dedicated SPF animal facilities for RCAS/TVA modelling, high-throughput drug screening suites, and single-cell genomics cores. Cross-disciplinary teams include bioinformaticians, translational pharmacologists, and clinician-scientists to accelerate bench-to-bedside translation.

Official University Profile

Matthew VanBrocklinView profile

Associate Professor

University of UtahUnited States

Matthew VanBrocklin is an Associate Professor of Surgery at the University of Utah School of Medicine and holds an adjunct appointment as Associate Professor of Oncological Sciences. His laboratory focuses on melanoma biology, CRISPR-based cancer modeling, oncolytic immunotherapy, and immune checkpoint biology, with translational goals of improving therapeutic strategies for melanoma and other solid tumors. Education: B.S., Western Michigan University M.S., Mayo Graduate School Ph.D., Western Michigan University Research Interests: Dr. VanBrocklin’s research spans four integrated themes: RCAS-TVA melanoma modeling: identifying novel melanoma drivers (NF1, KIT, RAC1, PDGFRA) and resistance mechanisms. CRISPR/Homology Directed Repair: developing single-vector CRISPR-HDR systems for in vivo cancer and monogenic disease modeling. Immune checkpoint biology: dissecting how B7-H3 and B7-H4 ligands enable immune evasion and designing blocking antibodies. Oncolytic immunotherapy: engineering RNA viruses with tumor-restricted tropism and combining them with checkpoint blockade. His work employs sophisticated mouse models, CRISPR gene editing, virology, immunology, and preclinical drug evaluation to accelerate discovery and translation. Scientific Awards & Honors: None explicitly listed in the provided text. Funding & Collaborations: Although specific grants are not detailed, his active translational studies—including longitudinal patient sample analyses with Dr. Robert Andtbacka—indicate robust funding and collaborative networks. Laboratory & Affiliations: Dr. VanBrocklin leads a research group within the Molecular Biology Program at the University of Utah and is affiliated with the Huntsman Cancer Institute (email domain: hci.utah.edu). His lab maintains cutting-edge facilities for viral vector production, CRISPR engineering, and in vivo tumor modeling.

Official University Profile

Berkley GryderView profile

Assistant Professor

Case Western Reserve UniversityUnited States

Berkley Gryder, PhD is an Assistant Professor in the Department of Genetics and Genome Sciences at Case Western Reserve University School of Medicine , with secondary appointments in the Case Comprehensive Cancer Center and the Angie Fowler Adolescent and Young Adult Cancer Research Initiative. His interdisciplinary work bridges chemistry, molecular biology, and computational science to investigate cancer epigenetics and transcriptional control. Research areas include: 3D genome organization in cancer Nuclear condensate formation Chemical strategies targeting transcription Single-cell epigenetic analysis Machine learning applications in genomics Novel wet-lab technologies Recent publications focus on nuclear phase separation, chromatin architecture in rhabdomyosarcoma, and chemical approaches to disrupt oncogenic transcriptional programs. Collaborations span medical oncology and medicinal chemistry teams across multiple institutions. Key article trends (2018-2025) reveal expertise in: Transcriptional condensates PAX3-FOXO1 fusion mechanisms Super-enhancer biology RNA Pol2 cluster dynamics Epigenetic plasticity in resistance 3D genomics technologies (AQuA-HiChIP)

Official University Profile

Helen E. BlackwellView profile

Professor

University of Wisconsin-MadisonUnited States

Helen E. Blackwell is the Norman C. Craig Professor of Chemistry at the University of Wisconsin–Madison, where she has served on the faculty since 2002. She directs the Blackwell Lab within the Department of Chemistry, leading an interdisciplinary program that merges organic synthesis, microbiology, and materials science to understand and manipulate bacterial quorum sensing. Education & Training B.A., Oberlin College (1994) Ph.D., Chemistry, California Institute of Technology (1999) Postdoctoral Fellow, Harvard University (1999–2002) Research Overview The Blackwell group designs small molecules, peptidomimetics, and smart materials that intercept bacterial communication pathways known as quorum sensing. By targeting LuxR-type receptors in Gram-negative pathogens and AgrC-type receptors in Gram-positive pathogens, her work provides molecular tools to dissect signal transduction and to attenuate virulence without killing bacteria—an anti-virulence strategy aimed at reducing resistance pressure. Complementary efforts combine microwave-assisted combinatorial chemistry with spatially addressable macroarrays to rapidly generate and screen focused libraries of bioactive compounds. A parallel track explores materials chemistry: the group engineers slippery liquid-infused porous surfaces (SLIPS) and biodegradable polymer coatings that release quorum-sensing modulators, preventing biofilm formation on medical devices and wound dressings in collaboration with the Lynn laboratory. Publication Trends Over the past two decades Blackwell has authored >200 peer-reviewed articles. Recent work (2022-2025) emphasizes structure–function analyses of LasR, RhlR, and QscR receptors in Pseudomonas aeruginosa , elucidation of AgrC signaling in staphylococci, and development of in-vivo-active peptidomimetics. A notable trend is the integration of high-resolution structural biology, single-cell imaging, and mouse infection models to translate synthetic modulators from bench to pre-clinical evaluation. Awards & Recognition Norman C. Craig Professorship (endowed chair) Multiple NIH R01 and NSF grants supporting chemical biology and antimicrobial research Highly cited researcher in quorum sensing and chemical microbiology Training & Mentorship Blackwell has mentored 20+ Ph.D. students, 15 post-doctoral researchers, >50 undergraduate researchers, and visiting scholars. Alumni occupy tenure-track positions and leadership roles in biotech, pharma, and academia. Laboratory Culture The Blackwell Lab is committed to an inclusive, supportive environment that fosters creativity and interdisciplinary collaboration. Weekly group meetings, individualized mentoring, and outreach activities (public lectures, high-school workshops) reinforce the mission of translating chemical insights into societal benefit.

Official University Profile

Paul MeakinView profile

Associate Professor

University of LeedsUnited Kingdom

Dr. Paul Meakin is a BHF Intermediate Basic Science Research Fellow and Associate Professor at the University of Leeds , affiliated with the School of Medicine . His work bridges cardiovascular disease, Type 2 diabetes, and Alzheimer's disease, focusing on the ß-secretase enzyme (BACE1) as a therapeutic target. Education: MSci in Biochemistry and Biological Chemistry, University of Nottingham (2004) PhD in Molecular Physiology, University of Dundee (2009) Research Interests: Cardiovascular-metabolic-neurodegenerative intersections, BACE1 enzyme regulation , endothelial cell dysfunction, and vascular remodeling in diabetes. His lab investigates how BACE1 inhibition can prevent vascular complications in metabolic diseases. Publications Trends: His 15 most recent articles (2025-2013) center on BACE1's role in vascular health, diabetes-induced atherosclerosis, fibrosis in systemic sclerosis, and amyloid-related pathologies. They explore in vivo models, signaling pathways (Wnt/β-catenin, Notch), and translational strategies like repurposing BACE1 inhibitors for cardiometabolic applications. Scientific Recognition: Nick Hales Young Investigator Award (2017, 2014) Professional Leadership: Co-lead of the Physiology Society’s Metabolic Physiology Theme (2019-2022) and committee member of the British Microcirculation Society (2019-2022). Research Groups: Affiliated with the Leeds Institute of Cardiovascular and Metabolic Medicine and the Multidisciplinary Cardiovascular Research Centre , focusing on Discovery and Translational Science in cardiometabolic health.

Official University Profile

Isaac S. HarrisView profile

Assistant Professor

University of RochesterUnited States

Isaac S. Harris is an Assistant Professor at the University of Rochester Medical Center's School of Medicine and Dentistry and Wilmot Cancer Institute, where he leads independent research since September 2019. He received his PhD from the University of Toronto under Dr. Tak Mak and pursued postdoctoral training at Harvard Medical School with Dr. Joan Brugge. Appointments: Department of Biomedical Genetics; Department of Pharmacology and Physiology Research Focus: Antioxidant biology in cancer, particularly glutathione (GSH) and redox regulation Technologies: Developer of Multifunctional Approach to Pharmacologic Screening (MAPS) Research Interests: Dr. Harris investigates how cancer cells exploit antioxidant systems like GSH for tumor initiation and progression. His lab combines in vivo mouse models with high-throughput pharmacologic screening to uncover metabolic vulnerabilities in cancer cells. Key projects explore: GSH's role in cancer initiation and protein homeostasis Redox signaling in tumor microenvironment Metabolic compensation pathways in antioxidant-deprived cancers Development of novel screening technologies (MAPS) Interactions between antioxidant pathways and cell death mechanisms Cross-talk between redox regulation and kinase signaling Publications & Technology: The Harris Lab has published extensively on GSH metabolism in cancer, including breakthrough studies on: Deubiquitinase inhibition as a therapeutic strategy Redox regulation of Th17 and regulatory T cells Cancer cell adaptation to antioxidant depletion Development of physiologic medium screening platforms Lab Members: Current researchers include graduate students Fatemeh Alimohammadi, Gloria Asantewaa, Marco Zocchi, and TashJaé Scales. Alumni include Hayley Chang (MD/PhD student) and technician Leo Schiller.

Official University Profile

Anne E. NicholsView profile

Assistant Professor

University of RochesterUnited States

Anne E. Nichols is an Assistant Professor in the Department of Orthopaedics and Rehabilitation at the University of Rochester Medical Center, focusing on musculoskeletal research. She leads the Nichols Lab , which investigates tendon homeostasis, fibrosis, regeneration, and mechanobiology through genetic mouse models, single-cell sequencing, and tissue engineering. PhD in Biomedical and Veterinary Sciences (Regenerative Medicine), Virginia Tech (2018) BS in Biology, James Madison University (2008) Postdoctoral Fellow, Center for Musculoskeletal Research, URMC (2018-2022) Her research explores cellular communication in tendon pathology , epitenon progenitor roles , and therapeutic targets for fibrosis and regeneration . Recent work includes nanoparticle drug delivery systems and mechanotransduction studies to improve healing outcomes. Key scientific awards include: NIH Pathway to Independence Award (K99/R00, 2022-2027) ORS New Investigator Recognition Award (2021) Orthoregeneration Network Foundation Grant (2020) Stamps Family Graduate Fellowship (2012-2018) Collaborations span orthopaedic research , biomedical engineering , and musculoskeletal disease . The lab welcomes applications from undergraduates, graduate students, and postdocs.

Official University Profile

Xiaowei WuView profile

Assistant Professor

Virginia Polytechnic Institute and State UniversityUnited States

Xiaowei Wu is an Assistant Professor in the Department of Statistics at Virginia Polytechnic Institute and State University, part of the College of Science. He holds a Ph.D. in Statistics from Rice University (2010), and M.S. and B.S. degrees in Electrical Engineering from Wuhan University, China (2003 and 1997, respectively). His research focuses on statistical genetics, bioinformatics, Bayesian methods, and stochastic population dynamics. Key areas include mutation rate estimation, epigenetic analysis, and computational tools for genomic data. Teaching includes courses like Advanced Statistical Genomics and Probability & Statistics for Electrical Engineers. His work bridges theoretical statistics with applications in genetics, neurology, and environmental health. Notable contributions include developing simulation frameworks (e.g., SimuBP) and methodologies for analyzing genetic and epigenetic data. Current projects address antimicrobial resistance, neurological disorder genetics, and machine learning in clinical prediction. Publications span journals in stochastic analysis, genetics, and bioinformatics, with emphasis on branching processes, mutation dynamics, and genomic variant detection. He collaborates across disciplines to advance quantitative methods in life sciences and healthcare.

Official University Profile

Melanie GartzView profile

Assistant Professor

Medical College of WisconsinUnited States

Melanie Gartz, PhD, MS, MHS, is an Assistant Professor in the Department of Cell Biology, Neurobiology and Anatomy at the Medical College of Wisconsin (MCW). She holds academic qualifications including a PhD in Cellular and Developmental Biology (2020), MS (2014), MHS (2011), and BS (2009). Her roles include teaching in MCW’s medical and graduate programs, focusing on clinical anatomy and molecular/cellular research pathways. She has developed the Musculoskeletal Skin block in the new curriculum and engages in interprofessional education. Her research interests center on modeling genetic neuromuscular diseases using induced pluripotent stem cells (iPSCs), particularly Duchenne Muscular Dystrophy and Nemaline Myopathy. Key areas include mitochondrial dysfunction, exosome-mediated communication, and disease mechanisms in cardiomyocytes and skeletal myocytes. Her lab investigates pathways like oxidative stress and exosome signaling to understand disease progression. Dr. Gartz has received over 15 awards, including the Karen Marcdante Bravery in Teaching Award (2022) and multiple 'Outstanding Medical Student Teacher' recognitions. Her 15+ publications span exosome biology, microRNA regulation, and iPSC-derived disease models. She leads grants exploring exosome-based therapies and cardiac dysfunction in muscular dystrophies. She mentors students across levels, from high school to medical school, and contributes to community outreach via 'Anatomy Nights' and STEM education initiatives. Collaborations include the Kern Institute’s KINETIC3 Scholar program and the Medical College of Wisconsin Cardiovascular Center.

Official University Profile

Frank T. HorriganView profile

Associate Professor

Baylor College of MedicineUnited States

Frank T. Horrigan, Ph.D., is an Associate Professor at Baylor College of Medicine’s Graduate School of Biomedical Sciences, affiliated with the Department of Molecular Physiology and Biophysics. He holds membership in the Dan L Duncan Comprehensive Cancer Center and participates in graduate programs in Development, Disease Models & Therapeutics, and Chemical, Physical & Structural Biology. His research focuses on ion channel gating mechanisms, particularly the large conductance Ca²⁺-activated K⁺ (BK) channel, exploring how voltage sensors, Ca²⁺ binding, and Mg²⁺ influence channel activity. Techniques used include patch clamping, mutagenesis, and computational modeling. Education: Ph.D. from Stanford University (1991), postdoctoral training at Stanford (2000) and the University of Miami (1995). His work bridges basic science and therapeutic applications, targeting diseases like hypertension and rheumatoid arthritis. The Horrigan Lab collaborates on projects involving ion channel dysfunction in cardiovascular and neurological disorders. Key research themes include allosteric regulation of BK channels, drug modulation of ion channels, and the role of metal ions (Cu²⁺, Mg²⁺, heme) in channel function. The lab’s findings contribute to understanding disease mechanisms and drug development strategies. Current lab members include Postdoctoral Associate Liang Sun.

Official University Profile